Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance.

NCT04624568 is registered in ClinicalTrials.gov with Centre Hospitalier Régional d'Orléans as lead sponsor.

NCT NCT04624568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04624568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance.
Lead sponsor
Centre Hospitalier Régional d'Orléans
Phase
Not applicable
Overall status
Completed
Start date
November 17, 2020
Completion date
May 17, 2023
Enrollment
81 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervix lesion, human papilloma virus infection, squamous intraepithelial lesions of the cervix